Xenon improves long-term cognitive function, reduces neuronal loss and chronic neuroinflammation, and improves survival after traumatic brain injury in mice

Rita Campos-Pires¹,²,³, Tobias Hirnet⁴, Flavia Valeo¹, Bee Eng Ong¹, Konstantin Radyushkin⁵, Jitka Aldhoun¹, Joanna Saville¹, Christopher J. Edge⁶,⁷, Nicholas P. Franks⁶, Serge C. Thal⁴,* and Robert Dickinson¹,²,*

¹Anaesthetics, Pain Medicine and Intensive Care Section, Department of Surgery and Cancer, UK, ²Royal British Legion Centre for Blast Injury Studies, Department of Bioengineering, Imperial College London, UK, ³Charing Cross Hospital Intensive Care Unit, Critical Care Directorate, Imperial College Healthcare NHS Trust, London, UK, ⁴Department of Anaesthesiology, Medical Centre of Johannes Gutenberg University, Mainz, Germany, ⁵Mouse Behavioural Outcome Unit, Focus Program Translational Neurosciences, Johannes Gutenberg University, Mainz, Germany, ⁶Department of Life Sciences, Imperial College London, UK and ⁷Department of Anaesthetics, Royal Berkshire Hospital NHS Foundation Trust, Reading, UK

*Corresponding authors. E-mails: thal@uni-mainz.de, r.dickinson@imperial.ac.uk

This article is accompanied by an editorial: Xenon for traumatic brain injury: a noble step forward and a wet blanket by Terrando & Warner, Br J Anaesth 2019;123:9–11, doi: 10.1016/j.bja.2019.04.004

Abstract

Background: Xenon is a noble gas with neuroprotective properties that can improve short and long-term outcomes in young adult mice after controlled cortical impact. This follow-up study investigates the effects of xenon on very long-term outcomes and survival.

Methods: C57BL/6N young adult male mice (n=72) received single controlled cortical impact or sham surgery and were treated with either xenon (75% Xe:25% O₂) or control gas (75% N₂:25% O₂). Outcomes measured were: (i) 24 h lesion volume and neurological outcome score; (ii) contextual fear conditioning at 2 weeks and 20 months; (iii) corpus callosum white matter quantification; (iv) immunohistological assessment of neuroinflammation and neuronal loss; and (v) long-term survival.

Results: Xenon treatment significantly reduced secondary injury (P<0.05), improved short-term vestibulomotor function (P<0.01), and prevented development of very late-onset traumatic brain injury (TBI)-related memory deficits. Xenon treatment reduced white matter loss in the contralateral corpus callosum and neuronal loss in the contralateral hippocampal CA1 and dentate gyrus areas at 20 months. Xenon’s long-term neuroprotective effects were associated with a significant (P<0.05) reduction in neuroinflammation in multiple brain areas involved in associative memory, including
Traumatic brain injury (TBI) is a complex and heterogeneous disorder representing a significant global healthcare burden. In Europe, the annual incidence of TBI has been estimated at 326 per 100 000 population. Those patients who survive TBI frequently suffer from debilitating conditions that limit their ability to work or re-integrate to society, and have an increased risk of death. A recent long-term observational study on TBI patients aged 15–54 yr calculated a 7-fold increase in risk of death up to 13 yr after hospital admission. In Europe, ~7.7 million people are living with TBI-related disability. It is becoming clear that even a single TBI early in life is a risk factor for developing cognitive dysfunction, Alzheimer’s disease (AD), and other neurodegenerative conditions later in life.

Current clinical treatment for TBI patients is largely supportive, centred on non-specific endpoints such as management of tissue oxygenation, cerebral perfusion pressure and intracranial pressure. At present, there are no clinically proven specific neuroprotective drugs for TBI. There is a need for neuroprotective treatments that minimise brain damage after TBI and improve long-term outcomes and survival.

Xenon is an anaesthetic noble gas that is neuroprotective in models of ischaemic brain injury. Xenon has recently been shown to be effective in reducing white matter damage in humans after ischaemic brain injury resulting from out-of-hospital cardiac arrest. Xenon is protective in in vitro models of brain trauma, but much less is known about its effects in brain trauma in vivo. We previously showed in an animal model that administration of xenon after TBI improves short-term (up to 4 days) and long-term outcomes (28 days) in mice. The current study is a long-term follow-up that evaluates the effect of xenon administered to young adult male mice shortly after experimental brain trauma, investigating cognitive function, brain histology, and survival up to 20 months after TBI, which is approaching the end of a healthy animal’s life span. We used the rodent controlled cortical impact (CCI) brain trauma model to test the following hypotheses: (1) xenon treatment after TBI improves very long-term cognitive and histological outcomes (at 20 months); and (2) xenon treatment after TBI improves survival at (i) 12 months and (ii) the end of the study (20 months).

**Methods**

All experiments were approved by the Animal Ethics Committee of the Landesuntersuchungsamt Rheinland-Pfalz (protocol number: G12-1-010). We designed our study to comply with ARRIVE (Animal Research: Reporting of In Vivo Experiments) guidelines. Adult male C57BL/6N mice (n=77), aged 2.5 months, mean weight (standard error of the mean [SEM]) 23.9 (0.1) g at the time of surgery or perfusion for naïve animals, were obtained from Charles River Laboratory (Sulzfeld, Germany). Animals were housed in filter-top cages in a pathogen-free facility in a 12:12 light–dark cycle (7 AM–7 PM) light at 22°C with ad libitum access to food and water. Animals were closely monitored in the postoperative period for at least 4 h, and then early the following day. Long-term survival animals were checked at least once daily throughout the study.

**Experimental groups, randomisation, and blinding**

Animals were randomly assigned to CCI primary injury (no treatment) or CCI followed by 75% Xe:25% O2 or CCI followed by 75% N2:25% O2 (control gas) or sham surgery followed by 75% N2:25% O2 (control gas) groups. The experimenter performing the CCI surgery was blinded to treatment. A separate experimenter, blinded to groups and treatment, performed behavioural tests. For cohort 1 (n=22), there were nine animals in each 24 h group (CCI control; CCI xenon) and four animals in the primary injury group. Animals were allowed to survive for 15 min (primary injury group) or 24 h. In cohort 2 (n=50), long-term (20 month) survival experiments had 20 animals each in the CCI xenon and CCI control groups, and 10 animals in the sham-surgery group. For cohort 3 (n=5), a naïve group of five animals aged 2.5 months was included for comparison of hemisphere volume and cerebral white matter with the long-term cohort.

**Traumatic brain injury**

Animals were anaesthetised with 3.5 vol% sevoflurane in an air/oxygen mixture (40% O2:60% N2) supplied via a facemask in spontaneously breathing animals with buprenorphine analgesia (0.1 mg kg⁻¹). Core body temperature was monitored and maintained at 37°C for the duration of the surgery by means of a rectal probe and feedback-controlled heating pad."
Sachs, March-Hugstetten, Germany). Traumatic injury was performed using the CCI model, as described previously.\textsuperscript{16} Animals were fixed in a stereotaxic frame (Kopf Instruments, Tujunga, CA, USA) and a 4 × 5 mm craniotomy window was created using a saline-cooled, high-speed drill along the coronal and lambdoid sutures and laterally as close as possible to the temporalis muscle insertion. The bone flap was lifted exposing the dura above the right parietal cortex, between the sagittal, lambdoid, and coronal sutures. The tip of a custom-built CCI device (L. Kopacz, Mainz, Germany) was positioned above the intact dura in the centre of the craniotomy window (1 mm from sagittal suture and 1 mm from lambdoid suture). The angle of the impactor, typically 25° from the sagittal plane, was adjusted such that the tip was perpendicular to the dural surface. The impactor tip was flat, with a diameter of 3 mm, impact velocity of 8 m s\textsuperscript{-1}, impact duration of 150 ms, and penetration depth of 1.0 mm. Our CCI impact parameters and the functional and histological outcomes are similar to those classified as a moderate–severe injury.\textsuperscript{18} After CCI surgery, the craniotomy was closed with the bone flap, sealed with tissue glue (Histoacryl; Braun-Melsungen, Melsungen, Germany), and the skin sutured. Sham-surgery animals underwent identical anaesthesia, temperature control, placement in stereotaxic frame, surgical skin incision to reveal the surface of the skull, which was drilled superficially, but no craniotomy was performed. The duration of the sham surgery and anaesthesia was identical to that of the CCI animals. In order to avoid any confounding effects from the anaesthesia and analgesia we were careful to ensure that the sham group received exactly the same drugs. The choice of anaesthetic and analgesic drugs in animal TBI studies may also have an impact on how secondary injury develops. For our study we chose to combine sevoflurane and buprenorphine. Sevoflurane has been shown to have minimal effects on secondary injury development in TBI models.\textsuperscript{19} Buprenorphine is a highly effective and safe analgesic in rodents.\textsuperscript{20,21} Despite some controversy surrounding opioid effects on TBI outcomes in rodents,\textsuperscript{22,23} evidence is limited. Interestingly, buprenorphine has been shown to have no impact on injury development in rodent models of brain ischaemia.\textsuperscript{24,25} Overall, the benefits of appropriate intraoperative and postoperative analgesia are well described, and mandatory for ethical and animal welfare. Animals were returned to their individual home cages in a heated incubator (33°C, 35% humidity; IC8000; Draeger, Lübeck, Germany) and allowed to recover for 15 min before treatment, breathing room air.

Xenon or control gas administration

Gas treatments were administered to spontaneously breathing animals in a series of custom-made xenon exposure chambers linked in a closed circuit, for a total duration of 3 h, starting 15 min after CCI injury. Gas concentrations inside the circuit were monitored continuously via a xenon meter (model 439 EX; Nyquist Ltd, Congleton, UK) and an oxygen meter (Oxydig; Draeger). Carbon dioxide was removed from the system using soda lime pellets. Additional volumes of gases were added as necessary to maintain concentrations of 21–25% for oxygen and 70–75% for xenon throughout the 3 h administration period. Gases were circulated at 700 ml min\textsuperscript{-1} by a small animal ventilator (Inspira ASV; Harvard Apparatus, Holliston, MA, USA). Xenon (BOC HiQ 74.96% xenon: 25.04% oxygen) was obtained from BOC Ltd (Guildford, UK). The exposure chambers were housed inside a heated incubator. After the 3 h treatment with xenon or control gas, animals were returned to the home cage where they breathed room air.

Quantification of functional outcome

Neuroscore

Functional outcome before and after CCI injury was determined using a 15-point neurological outcome score evaluating locomotor ability, vestibulomotor function, and general behaviour.\textsuperscript{16,26} The neuroscore was performed in real time before CCI surgery and repeated 24 h after injury by an experimenter blinded to the surgical and treatment groups. Because the sham-surgery animals had the same skin incision and sutures as the CCI animals, they were not visually distinguishable.

Contextual fear conditioning

Two weeks and 20 months after the injury, cognitive function was assessed in the same cohort of animals by a contextual fear conditioning test implemented using a multiconditioning system (TSE Systems GmbH, Bad Homburg, Germany). The test measures hippocampus-dependent contextual place memory. For the 2 week and 20 month tests, entirely different contexts (chambers) were used in order to test memory of novel environments. These tests were carried out by another blinded observer. For context conditioning training, an animal was placed inside a conditioning context Plexiglas chamber (36 × 20 × 20 cm) with a removable shock grid made of stainless steel rods (4 mm in diameter, spaced 6 mm apart). After 2 min, animals received a first electrical shock (0.4 mA, 2 s) and 15 s later a second shock with the same characteristics. Animal behaviour was recorded by a video camera to monitor freezing behaviour, defined as the lack of movement (excluding respiratory movements). The analysis of the freezing behaviour was performed using computerised video software (EthovisionXT software; Noldus Information Technology, Wageningen, The Netherlands). The contextual memory test was performed 24 h after context conditioning training. Mice were monitored for freezing for 2 min in the same context chamber that was used for training. The cumulative duration (s) of freezing behaviour during the 2 min of testing was used.

Survival analysis

The long-term survival cohort was kept for 20 months after CCI surgery to assess survival. Animals were monitored on a daily basis. Deaths that occurred up to the end of the observation protocol were spontaneous, and no animals had to be euthanised.

Histological processing

At 15 min and 24 h animals were anaesthetised with sevoflurane and euthanised by cervical dislocation. Brains were carefully removed, frozen on powdered dry ice, and stored at −80°C. At 20 months the surviving cohort of animals were terminally anaesthetised with pentobarbital and transcardially perfused with 20 ml of cold phosphate-buffered saline (PBS; Biochrom GmbH, Berlin, Germany) followed by 30 ml of cold 4% paraformaldehyde (DAC paraformaldehyde; Merck KGaA, Darmstadt, Germany). Brains were carefully removed from the skull and post-fixed in 4% paraformaldehyde (in PBS) overnight at
4 °C, then transferred to 30% sucrose in PBS until the brains sank, before being frozen as described above. Naive animals were terminally anaesthetised and perfused in the same manner. Frozen brains were embedded in Optimal Cutting Temperature mounting medium (Cell Path Ltd, Newton, Powys, UK) and cut in the coronal plane with a cryostat tissue slicer (Microm HM 560 [15 min, 24 h] or CryoStar NX70 [20 month, naïve]; Thermo Scientific, Walldorf, Germany). To quantify lesion volume, for each brain a total of 16–18 sections (10 µm thick) spanning the entire lesion were collected on Superfrost® Plus microscope slides (Thermo Fisher Scientific, Braunschweig, Germany) every 500 µm, starting at Bregma +3.14 mm. For immunohistochemistry on the long-term brains, 20 µm-thick slices were also obtained at a brain point 4.5 mm from the anterior pole of each brain (because of variable atrophy in the aged brains, these slices ranged from Bregma −1.25 and −2.15 mm when mapped to the Allen mouse brain atlas).27,28

Quantification of contusion volume

Slices (10 µm) were stained with cresyl violet (Merck Millipore, Darmstadt, Germany) as described.22 Slices were imaged with a digital camera (Scopetek DCM510; Scopetek Opto-Eletric Co. [Hangzhou, China] or Zeiss Axiocam 105 colour; Zeiss [Jena, Germany]) attached to a stereomicroscope (Wild model M8, Heerbrugg, Switzerland or Zeiss Stemi 305, Zeiss). The contusion was evident from a clear difference in the intensity of the cresyl staining. The area of the contusion was measured using image analysis software (Scopeshot 3.1, Scopetek Opto-Eletric Co. or Zen, Zeiss) by an investigator blinded to the experimental groups. Contusion volume was calculated by multiplying contusion areas, A, by the distance between brain sections, d (500 µm), according to the following formula:

\[
d \frac{1}{2} \left( A_1 + A_n \right) + d \left( A_2 + A_3 + \ldots + A_n \right)
\]

Secondary injury volume at 24 h was calculated by subtracting the mean primary injury contusion volume at 15 min from the total contusion volume measured at 24 h.

Quantification of area of myelinated fibres in the corpus callosum

Slices (10 µm) were stained overnight with 1% w/v Luxol Fast Blue in 95% isopropanol:5% acetic acid (10%) at 60 °C in a humidified water bath. Slices were washed briefly in 95% isopropanol followed by distilled water. Slices were differentiated in 0.5% w/v lithium carbonate for 30 s, followed by 70% isopropanol for 30 s followed by distilled water, then counterstained with cresyl violet. Slices (Bregma −1.94 mm) were imaged with a digital camera (Zeiss Axiocam 105 colour; Zeiss) attached to a stereomicroscope (Zeiss Stemi 305, Zeiss). The area of the contralateral corpus callosum was measured by a blinded investigator from the midline to a point directly above the distal end of the dentate gyrus (DG) granule cell layer using the area measurement function in ImageJ (FIJI). The GFAP positive area was quantified as percentage area (%-area) in the corpus callosum and in defined regions of interest (ROIs) (Fig. 1a) in the hypothalamus, retrosplenial cortex, amygdala, and hippocampal CA1, CA2, CA3, and DG regions, after rolling ball background subtraction and thresholding (equally for all images) to best match the raw image. For quantification of GFAP positive scar bordering the lesion cavity, images were thresholded (equally for all images) to best match the raw image and the area of interest delineated with a polygon selection in the retrosplenial and the somatosensory cortex. The GFAP-positive total stained area (µm²) and the length (µm) of the ROI were used to calculate an average scar thickness (µm) at the lesion cavity using ImageJ (FIJI). GFAP is upregulated when astrocytes become reactive, and is a reliable and sensitive marker of most reactive astrocytes.31 Because we were interested in quantifying reactive astrogliosis we chose to measure the percentage area of GFAP positive immunoreactivity, rather than count the absolute number of astrocytes. The number of Iba1 positive cells was manually counted in the same defined ROIs as above (Fig. 1a). NeuN positive cells were manually counted in the same ROIs as above for hypothalamus, retrosplenial cortex, and amygdala. For quantification of NeuN positive cells in the hippocampus, we used rectangular ROIs, parallel to and centred on the pyramidal cell layers—CA1 300 × 50 µm, CA2 200 × 50 µm, CA3 150 × 300 µm, and DG 2 × 300 × 80 µm boxes—one in each arm. In all of the long-term histology, TBI control and TBI xenon groups were compared with the sham group that was the same age and had been treated identically to the TBI groups but without impact, in...
order to ensure that any effects are independent of age-related changes in particular cell types or immunoreactivity.

Statistics
Data were assessed for normality using the Shapiro–Wilk test. We assessed significance of differences in contusion volume, secondary injury volume, and neurological outcome score between TBI control and TBI xenon groups using a two-tailed Student’s t-test. For the fear conditioning test and hemisphere volume data, we compared sham, TBI control, and TBI xenon groups using two-way analysis of variance (ANOVA) or one-way ANOVA, respectively, with Bonferroni’s post hoc test. Data on corpus callosum area, GFAP positive area, and Iba1 in the corpus callosum were analysed using one-way ANOVA with Bonferroni’s post hoc test. In order to test the hypothesis that xenon treatment reduces astrocytic scarring, the GFAP positive scar data were analysed using a one-tailed Student’s t-test. Normality tests, ANOVA, and Student’s t-tests were implemented using Graphpad Prism Version 7 software (GraphPad

Fig. 1. (a) A typical GFAP stained brain slice at Bregma −1.75 mm from a TBI control animal 20 months after injury. GFAP positive area was measured in the retrosplenial cortex (R), hypothalamus (Hy), amygdala (Am) and the hippocampus (CA1, CA2, CA3, and DG regions). The lesion on the right side of the cortex is clearly visible on the right of the image. For the retrosplenial cortex the dimensions of the region of interest (ROI) was an ellipse of 240 μm (width) × 605 μm (height); for the hypothalamus the ROI was a circle of diameter 600 μm; for the amygdala the ROI was a circle of diameter 750 μm; the ROIs for the hippocampus were drawn manually for each slice (using the Allen mouse brain atlas as a reference). Scale bar, 1000 μm. (b) Acute phase injury development. The controlled cortical impact model produces a primary lesion, clearly seen 15 min after trauma (hatched blue bar), with injury developing significantly 24 h after impact (control gas treatment); (n=4, TBI 15 min; n=9, TBI 24 h). (c) Xenon (red bar) significantly reduces secondary injury volume at 24 h compared with control gas (blue bar). Secondary injury is calculated by subtracting primary injury (15 min) from total contusion volume at 24 h (n=9, TBI control; n=9, TBI xenon). (d) Xenon improves short-term neurological outcome 24 h after injury (n=9, TBI control; n=9, TBI xenon). Control gas-treated animals (blue solid bars) received 75% nitrogen:25% oxygen. Xenon-treated animals (red bars) received 75% xenon:25% oxygen. Treatment was started 15 min after the impact and was administered for 3 h. Bars represent mean values and error bars are standard errors. *P<0.05; **P<0.01; ***P<0.001, compared with TBI control at 24 h. GFAP, glial fibrillary associated protein; DG, dentate gyrus; TBI, traumatic brain injury.
Results

Xenon treatment reduces secondary injury and improves outcome acutely after TBI

The injury parameters we used create a primary injury such that secondary injury develops significantly ($P<0.001$), increasing by 98% between 15 min and 24 h after trauma (Fig. 1b) in the TBI control group. Xenon treatment, starting 15 min after injury for 3 h, resulted in a significant reduction in secondary injury by 38% (5%) ($P<0.05$) at 24 h after injury (Fig. 1c). The reduction in secondary injury volume at 24 h translated into significant improvement in neurological outcome, with a 67% (11%) reduction ($P<0.01$) in neurological impairment score (Fig. 1d). Neurological outcome score was zero in all groups before CCI or sham surgery, and in the sham-surgery group 24 h later (data not shown).

TBI in young adult mice results in late-onset cognitive impairment that is prevented by xenon treatment

We investigated development of the cognitive phenotype at different time points after TBI in the same experimental cohort. We therefore investigated cognitive performance at 2 weeks and 20 months after injury, using a different contextual fear conditioning paradigm at each time point to investigate associative memory. At 2 weeks after injury, duration of immobilisation or ‘freezing’ in the pre-trial before fear conditioning was low for all groups (~6 s), and there was no significant difference between groups (Fig. 2a). At 24 h after the fear conditioning in context trial, all groups exhibited increased ‘freezing’ behaviour (~12 s) compared with pre-trial ($P<0.001$), indicating that they had remembered the context. However, at 2 weeks after injury there was no difference in the duration of freezing between groups (Fig. 2a), indicating all groups recalled the context to the same extent. The lack of difference in freezing time between sham and either of the TBI groups indicates that there was no early memory impairment. At the 20 month time point freezing time in the pre-trial was also low (<6 s) for all groups with no significant differences between groups. However, at the 20 month time point, in the context trial there was a

![Image](https://example.com/image.png)
significant reduction ($P<0.05$) in freezing duration in the TBI control group [29 (4) s] compared with the uninjured sham group [47 (3) s], indicating a late-onset memory impairment in the TBI control group (Fig. 2b). Interestingly, at the 20 month time point the xenon-treated TBI group showed no memory impairment as indicated by the fact that freezing duration [41 (5) s] was not significantly different to that of the sham group (Fig. 2b). This suggests that early xenon treatment after TBI prevents late-onset hippocampus-dependent memory impairment.

**Brain volume and lesion size 20 months after injury**

Compared with young adult naïve brains the brain hemisphere volumes of all groups were significantly ($P<0.0001$) smaller (Supplementary Fig. S1). The left and right hemisphere volumes in the sham group were respectively 28.1% (0.5%) and 30.5% (0.2%) smaller compared with the young naïve group. This is most likely caused by brain atrophy as a result of ageing, but we cannot exclude the possibility that anaesthesia and sham surgery are contributory factors. In the TBI control and TBI xenon groups, the contralateral (left) hemispheres were 30.3% (0.4%) and 27.8% (0.2%) smaller than the young naïve group. Traumatic lesions were present at 20 months in both TBI groups, but there was no difference in volume between the TBI control group [17.7 (1.9) mm$^3$, $n=8$] and the xenon-treated TBI group [17.6 (1.6) mm$^3$, $n=11$].

**Xenon treatment reduces long-term white matter degeneration after TBI**

In order to determine the effect of injury and xenon treatment on neuronal white matter 20 months after injury, we measured the area of myelinated fibre tracts stained with Luxol Fast Blue in the contralateral corpus callosum (Fig. 3a and b). The area of the corpus callosum in the sham group at 20 months was 0.23 (0.02) mm$^2$, which was not significantly different to that of the naïve group, aged 2.5 months, 0.20 (0.04) mm$^2$ (data not shown), indicating that in the absence of trauma there was no age-related neurodegeneration. However, in the TBI control group we observed a significant ($P<0.001$) reduction of 67% (13%) in white matter compared with the uninjured sham group. In contrast, the area of the contralateral corpus callosum myelinated fibre tracts in the TBI xenon group was significantly ($P<0.05$) larger, by 100% (14%), than the TBI control group and was not significantly different to the uninjured sham group. The reduction in white matter in the TBI control group was accompanied by a significant ($P<0.05$) increase in GFAP positive astrocytes in the corpus callosum compared with the sham group, whereas in the xenon-treated group.
TBI group GFAP positive staining was not significantly different to the sham group (Fig. 3c). There was a significant ($P<0.05$) increase in Iba1 positive microglia in the corpus callosum in both the TBI control and TBI xenon groups compared with the sham group (Fig. 3d).

Xenon treatment reduces chronic perilesional astrocytic scarring after TBI

We measured the thickness of the astrocytic scar bordering the lesion cavity in the retrosplenial cortex and somatosensory cortex (Fig. 4a and b) at 20 months after injury. The thickness of the astrocytic scar in the xenon-treated TBI group was significantly reduced compared with the TBI control group, by 45% (8%) ($P<0.01$) and 39% (8%) ($P<0.05$) in the retrosplenial cortex and somatosensory cortex, respectively (Fig. 4c and d).

Xenon reduces the chronic increase in GFAP expression induced by TBI

The GFAP stained area at 20 months after TBI was measured in four specific brain regions involved in contextual fear.
conditioning: the hypothalamus, amygdala, hippocampus and retrosplenial cortex.33–36 We found significantly increased GFAP stained area in both ipsilateral and contralateral hypothalamus and in the right retrosplenial cortex in the TBI control group compared with the sham group (p < 0.05 and p < 0.01 for the different regions, respectively). In the TBI xenon group, GFAP positive area was significantly reduced (p < 0.05) in the hypothalamus compared with the TBI control, with no significant difference between sham and TBI xenon groups (Fig. 5a and d). In the right retrosplenial cortex GFAP positive area was reduced in the xenon-treated TBI group compared with the TBI control group (Fig. 5d). We did not find significant differences between any of the groups in the other brain regions examined, amygdala or hippocampus (Fig. 5d; Supplementary Fig. S2a). In the sham group we observed differential expression of GFAP in different brain areas, with greatest expression in hippocampal CA1 and least in the retrosplenial cortex. Because we compared the same brain regions of the injured groups and sham group, variability between different brain regions did not impact the results.

**Xenon reduces microglial proliferation in the ipsilateral amygdala after TBI**

We measured the number of Iba1-positive microglia in the hypothalamus, amygdala, hippocampus, and retrosplenial cortex at 20 months after injury (Fig. 5b and e). We observed a significant (p < 0.05) increase in the number of Iba1-positive microglial cells in the TBI control group in the right amygdala, whereas the TBI xenon group was not different to the sham group in this region (Fig. 5e). No other significant differences from sham were observed (Fig. 5e, Supplementary Fig. S2b).

**Xenon reduces neuronal loss in the contralateral CA1 and DG after TBI**

We measured the number of NeuN-positive neurones in the hypothalamus, amygdala, hippocampus, and retrosplenial cortex (Fig. 5c and f). In the CA1 and DG of the hippocampus there was a significant (p < 0.05) decrease in the number of neurones in the TBI control group compared with the sham group, whereas the TBI xenon group was not different to the sham group (Fig. 5f). In the hypothalamus, retrosplenial cortex, amygdala (Fig. 5f), and CA2 and CA3 regions of the hippocampus (Supplementary Fig. 2c), there was no significant difference in the number of neurones in the TBI groups or the sham group.

**Effect of xenon treatment on survival after TBI**

Our hypotheses were that xenon treatment improves survival after TBI at 12 and 20 months after injury. All of the deaths that occurred up until the end of the observation period of 20 months were spontaneous. We analysed the data using Kaplan–Meier survival curves (Fig. 6). At both the 6 and 12 month time points, there was 20% mortality in the TBI control group whereas in the sham and TBI xenon groups mortality was 0%. The survival curve for the TBI xenon group was significantly different (p < 0.05) to that of the TBI control group at 12 months. Animals in the TBI control group were more likely to die than the TBI xenon group in the first 12 months with a hazard ratio of 8.38 (95% confidence interval [CI], 1.13–61.95). At the end of the observation period of 20 months, the mortality in the TBI control group was 60%, whereas in the sham group it was 30% and in the TBI xenon group it was 45%. At the end of the observation period (20 months), the survival curves for the TBI control and TBI xenon groups were not significantly different (p = 0.09); and the hazard ratio was 1.68 (95% CI, 0.70–4.00). The data as a whole show that xenon treatment significantly improves survival in the first 12 months after TBI.

**Discussion**

TBI is recognised as a dynamic condition with long-lasting sequelae that evolve in the weeks, months, and years after injury. Many of the long-term cognitive and motor impairments experienced by TBI patients result from the developing secondary injury arising after the primary insult. Survivors of TBI have a significantly increased risk of death, and it is known that even a single TBI early in life is a risk factor for developing AD, chronic traumatic encephalopathy (CTE), and other cognitive impairments later in life. The mechanistic link between TBI, AD, and CTE is not fully understood, but chronic neuroinflammation and neurodegeneration are thought to play key roles. Our aim was to investigate the effects of xenon treatment on secondary injury in both the short- and very long-term on behavioural outcomes longitudinally in an ageing cohort, and on survival, after a single TBI.

**Experimental paradigm**

The rodent CCI model is a widely used, highly reproducible, preclinical model of blunt TBI. With a few notable exceptions, the majority of studies using this model have investigated outcomes in the time frame of 1–28 days. Our
in later life. We examined a cognitive function, A single TBI early in life increases the risk of cognitive decline after TBI. Xenon treatment prevents late-onset memory deficits, consistent with a previous study where we showed that xenon also found a significant improvement in acute neurological impairment and improves short-term neurological parameters we used result in a clear early secondary injury, evidenced by the lesion volume approximately doubling in the first 24 h. This early secondary injury is accompanied by a moderate neurological impairment at this time point.

**Xenon treatment after TBI reduces acute secondary injury and improves short-term neurological impairment**

Our results show that xenon is effective in significantly reducing the developing secondary injury in the first 24 h. We also found a significant improvement in acute neurological outcome at 24 h in the xenon-treated group. These results are consistent with a previous study where we showed that xenon reduced total contusion volume, but we did not examine secondary injury separately.

**Xenon treatment prevents late-onset memory deficits after TBI**

A single TBI early in life increases the risk of cognitive decline in later life. We examined a cognitive function, hippocampus-dependent memory, in the same cohort, at 2 weeks and 20 months after traumatic injury. At the 2 week time point, no memory impairment was evident in either the TBI control or TBI xenon groups. In contrast, at 20 months in the TBI control group there was a significant memory impairment compared with the uninjured sham group. Remarkably, this late-onset cognitive impairment was absent in the TBI xenon group. The contextual fear conditioning paradigm we used is robust and one of the most comprehensively characterised rodent models of learning and memory. This test allowed us to use novel visuospatial contexts for the two time points and is not confounded by motor deficits. Although memory is a cognitive function, it is only one component of global cognition that can be assessed in patients. Nevertheless, our findings are of particular clinical relevance because of the association of TBI with increased risk of AD and other neurodegenerative conditions in which delayed onset memory impairment is observed. Our results suggest that xenon treatment may prevent development of these persistent cognitive deficits in TBI patients.

**Histopathological correlates of late-onset cognitive impairment are reduced by xenon**

Long-term loss of cerebral white matter after TBI is associated with cognitive impairment in patients. In the TBI control group we observed chronic neurodegeneration of white matter in the contralateral corpus callosum that was associated with reactive astrogliosis and an increase in microglia, similar to findings reported by Pischiutta et al. 12 months after CCI in mice. Remarkably xenon treatment reduced loss of white matter and chronic astrogliosis in the corpus callosum. Interestingly, microglia were significantly increased in the corpus callosum of both TBI control and TBI xenon groups, suggesting involvement of toxic A1-type reactive astrocytes induced by activated microglia in the chronic neurodegeneration. In addition to reducing reactive astrogliosis in the contralateral corpus callosum, xenon treatment resulted in a significant reduction in the thickness of astrocytic scarring bordering the lesion cavity in the retrosplenial and somatosensory cortex. We suggest that the reduced scarring limits neurodegeneration and promotes axonal repair in the perilesional tissue.

The neuronal circuit involved in contextual fear conditioning involves a number of brain regions, including the hippocampus, amygdala, retrosplenial cortex, and hypothalamus. We found neuronal loss in the CA1 and DG regions of the contralateral hippocampus in the TBI control group 20 months after TBI, consistent with the results of another study at 12 months after injury. Both of these regions are involved in episodic memory, and this neuronal loss in the TBI control group correlates with the late-onset memory impairment. Remarkably, xenon treatment reduced this long-term neurodegeneration, with the number of neurones in the CA1 region and the DG regions in the xenon-treated TBI group not different to the sham group, correlating with xenon preventing late-onset impairment of hippocampus-dependant memory. We found increased astrocyte reactivity in the hypothalamus and retrosplenial cortex of TBI control animals compared with the sham group. This is consistent with similar findings reported in the thalamus and cortex of mice 1 yr after CCI injury. Interestingly, in xenon-treated animals, the GFAP positive area was decreased in the retrosplenial cortex and was not different from the sham group in the hypothalamus. Hypothalamic dysfunction has been found in other rodent models of TBI, including evidence of persistent hypothalamic astrocytosis 2 months after CCI.
However, we did not observe significant changes in astrocyte reactivity in the amygdala or hippocampus. We observed increases in number of microglia in the right amygdala in the TBI control group but not in the xenon-treated group. The amygdala is involved in memory recall involving anxiety and fear responses, and this observation may play a role in xenon preventing long-term cognitive impairment. Our findings suggest that the learning and memory deficits developing late after the injury result from a combination of discrete injury, involving key brain areas such as CA1 and DG regions of the hippocampus, the hypothalamus, retrosplenial cortex, and amygdala, and reduction of connectivity resulting from loss of white matter. Overall, xenon treatment preserved neuronal white matter, and reduced neuronal loss in the hippocampal CA1 and DG regions, and this may explain how xenon treatment prevents the late-onset cognitive impairment. Xenon reduced chronic GFAP immunoreactivity, a well-known marker of astrocyte activation and neuroinflammation in the hypothalamus and retrosplenial cortex. Given the recent evidence of the role astrocytes play in regulating neuronal activity, it is worth noting that even in the absence of cytotoxic effects, changes in astrocyte number and reactivity may result in neuronal dysfunction. Hypothalamic dysfunction associated with TBI is not yet fully understood; however, this is known to contribute to cognitive deficits in TBI patients and is worth noting that even in the absence of cytotoxic effects, changes in astrocyte number and reactivity may result in neuronal dysfunction. Hypothalamic dysfunction associated with TBI is not yet fully understood; however, this is known to contribute to cognitive deficits in TBI patients, and disruption of sleep and circadian rhythm are observed in many TBI patients.

Xenon treatment improves survival after injury

TBI is associated with an increased risk of death in those who survive the initial injury. A longitudinal study following a large cohort of patients for up to 13 yr after TBI found that by the end of the study mortality was 40%. When compared with a control group, this represents an increase in mortality of 2.8-fold overall (all ages) and a 7-fold increase for those sustaining a TBI at 15–54 yr. We aimed to determine whether xenon treatment would increase survival in a cohort of mice that had sustained a single TBI early in life. Our cohort was aged 2.5 months (young adult) when they were subjected to CCI, and our objective was to study them until old age. Given the reported life span of male C57BL/6 mice of 23–30 months, we studied them for 20 months after injury (age 23 months), and determined whether there was an effect of treatment at 12 months and at the end of the study. We observed a greater number of deaths in the TBI control group compared with the TBI xenon group or sham group at all time points. Early deaths (6 months after injury) were observed in the TBI control group but not in any other group, which we attribute to an increased risk of death resulting from the TBI. Xenon treatment improved survival significantly in the first 12 months after injury. Interestingly, no animals in the TBI xenon group or the sham group died in the first 12 months. At 12 months the hazard ratio of the TBI control group compared with the TBI xenon group was 8.34, similar to the 7-fold increased risk of death in TBI patients suffering a TBI early in life. At 20 months there were more survivors in the xenon-treated group, with a hazard ratio of 1.68 (P=0.09). The lack of a significant difference between TBI control and TBI xenon groups at the end of the study likely reflects that this time point is very close to the normal expected life span. Nevertheless, these results show that xenon improves early survival after TBI, and further preclinical studies to investigate this are merited.

Clinical relevance

Our aim was to evaluate xenon’s potential as a treatment for TBI in clinically relevant settings, with xenon treatment 15 min after the trauma, based on a scenario where a TBI patient might receive medical attention at the scene of injury within 15–20 min. Although there may be limited circumstances when xenon could be administered within this time frame, it is possible that xenon could be given by first responders. The most likely treatment scenario would be on arrival at hospital, and xenon is effective even when treatment start time is delayed up to 3 h after injury. The 3 h duration of xenon treatment used is relatively short, and it is plausible that extending treatment time might result in greater neuroprotection. The mechanisms by which xenon reduces secondary injury may be pleotropic, but preventing or reducing glutamate excitotoxicity is likely to play an important role. Glutamate levels in TBI patients peak 24–72 h after injury. It is possible that xenon treatment given during the entire period that glutamate is elevated would be more efficacious. Current treatment for TBI patients is largely supportive, with no clinically proven treatments specifically targeting neuronal loss and neurodegeneration. Xenon is approved for clinical use as a general anaesthetic and has recently undergone clinical trials as a neuroprotectant for ischaemic brain injury in neonates and adult cardiac arrest patients. We show here that xenon treatment after TBI in mice reduces chronic neurodegeneration of cerebral white matter, reduces loss of hippocampal neurones, prevents late-onset TBI-related cognitive impairment, and improves long-term survival. These long-term improvements in clinically relevant outcomes and survival provide further support to the idea that xenon could be used as an early neuroprotective treatment in TBI patients.

Authors’ contributions

Study design/planning: RCP, KR, SCT, RD. Study conduct: RCP, TH, KR, RD. Data analysis: all authors. Drafting of the paper: RCP, SCT, RD. Revision of the paper: all authors.

Acknowledgements

We thank Frida Kornes, laboratory manager, and Christina Golz, Department of Anaesthesiology, Medical Centre of Johannes Gutenberg University, Mainz, Germany, for advice and technical support, Cristine Ostwald, Department of Neurosurgery, Medical Centre of Johannes Gutenberg University, Mainz, Germany, for assistance with Luxol Fast Blue staining, Michael Schaefer, Department of Anaesthesiology, Medical Centre of Johannes Gutenberg University, Mainz, Germany, for advice on immunostaining, Rushdie Abuhamdah, Department of Life Sciences, Imperial College London, UK, for assistance with data blinding, and Stephen Rothery, National Heart and Lung Institute, Imperial College London, UK, for advice on widefield microscopy and image analysis.
Declarations of interest

NPF is a named inventor on patents covering the use of xenon as a neuroprotectant and a shareholder in Neuroprotectexon Ltd., a spin-out company that seeks to commercialise the use of xenon as a neuroprotectant. The other authors declare that they have no conflicts of interest.

Funding

The Medical Research Council, London, UK (MR/N0277361/1; MC_PC_13064); European Society for Anaesthesiology, Brussels, Belgium; The Gas Safety Trust, London, UK; Royal British Legion Centre for Blast Injury Studies, Imperial College London, UK; Royal Centre for Defence Medicine, Birmingham, UK; The Association of Anaesthetists of Great Britain and Ireland, London, UK; National Institute of Academic Anaesthesia, London, UK. We acknowledge the financial support of the Royal British Legion. Rita Campos-Pires was the recipient of a doctoral training award from the Fundação para a Ciência e a Tecnologia, Lisbon, Portugal (SFRH/BD/78886/2011), and a scholarship from the Deutscher Akademischer Austauschdienst (DAAD), German Academic Exchange Service, Bonn, Germany (A/13/72143). Tobias Hirnet is funded by the tauschdienst (DAAD), German Academic Exchange Service, scholarship from the Deutscher Akademischer Austauschdienst (DAAD), German Academic Exchange Service, Bonn, Germany (A/13/72143). Flavia Valeo is the recipient of an Imperial College London President’s PhD scholarship, London, UK.

Appendix A. Supplementary data

Supplementary data related to this article can be found at https://doi.org/10.1016/j.bja.2019.02.032.

References

1. Maas AIR, Menon DK, Adelson PD, et al. Traumatic brain injury: integrated approaches to improve prevention, clinical care, and research. Lancet Neurol 2017; 16: 987–1048
2. Peeters W, van den Brande R, Polinder S, et al. Epidemiology of traumatic brain injury in Europe. Acta Neurochir (Wien) 2015; 157: 1683–96
3. McMillan TM, Teasdale GM. Death rate is increased for at least 7 years after head injury: a prospective study. Brain 2007; 130: 2520–7
4. McMillan TM, Teasdale GM, Weir CJ, Stewart E. Death after head injury: the 13 year outcome of a case control study. J Neurol Neurosurg Psychiatry 2011; 82: 931–5
5. Tagliaferri F, Compagnone C, Korsic M, Servadei F, Kraus J. A systematic review of brain injury epidemiology in Europe. Acta Neurochir (Wien) 2006; 148: 255–68
6. Smith DH, Johnson VE, Stewart W. Chronic neuropathologies of single and repetitive TBI: substrates of dementia? Nat Rev Neurol 2013; 9: 211–21
7. Martin D, Smith M. Medical management of severe traumatic brain injury. J Hosp Med 2004; 65: 674–80
8. Donnelly J, Czosnyka M, Adams H, et al. Twenty-five years of intracranial pressure monitoring after severe traumatic brain injury: a retrospective, single-center analysis. Neurosurgery 2018. https://doi.org/10.1093/neuros/nyy468
9. Janowitz T, Menon DK. Exploring new routes for neuroprotective drug development in traumatic brain injury. Sci Transl Med 2010; 2: 27rv1
10. Warner DS, Borel CO. Treatment of traumatic brain injury: one size does not fit all. Anesth Analg 2004; 99: 1208–10
11. Zoerle T, Carbonara M, Zanier ER, et al. Rethinking neuroprotection in severe traumatic brain injury: toward bedside neuroprotection. Front Neurol 2017; 8: 354
12. Laitio R, Hynninen M, Arola O, et al. Effect of inhaled xenon on cerebral white matter damage in comatose survivors of out-of-hospital cardiac arrest: a randomized clinical trial. JAMA 2016; 315: 1120–8
13. Campos-Pires R, Koziaikova M, Yonis A, et al. Xenon protects against blast-induced traumatic brain injury in an in vitro model. J Neurotrauma 2018; 35: 1037–44
14. Coburn M, Maze M, Franks NP. The neuroprotective effects of xenon and helium in an in vitro model of traumatic brain injury. Crit Care Med 2008; 36: 588–95
15. Harris K, Armstrong SP, Campos-Pires R, Kiru L, Franks NP, Dickinson R. Neuroprotection against traumatic brain injury by xenon, but not argon, is mediated by inhibition at the N-methyl-d-aspartate receptor glycine site. Anesthesiology 2013; 119: 1137–48
16. Campos-Pires R, Armstrong SP, Sebastiani A, et al. Xenon improves neurologic outcome and reduces secondary injury following trauma in an in vivo model of traumatic brain injury. Crit Care Med 2015; 43: 149–58
17. Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol 2010; 8, e1000412
18. Siebold L, Obenaus A, Goyal R. Criteria to define mild, moderate, and severe traumatic brain injury in the mouse controlled cortical impact model. Exp Neurol 2018; 310: 48–57
19. Luh C, Gierth K, Timaru-Kast R, Engelhard K, Werner C, Thal SC. Influence of a brief episode of anesthesia during the induction of experimental brain trauma on secondary brain damage and inflammation. PLoS One 2011; 6, e19948
20. Dahan A, Yassen A, Bijl H, et al. Comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans and rats. Br J Anaesth 2005; 94: 825–34
21. Guarnieri M, Brayton C, DeTolla L, Forbes-McBean N, Sarabia-Estrada R, Zadnik P. Safety and efficacy of buprenorphine for analgesia in laboratory mice and rats. Lab Anim (NY) 2012; 41: 337–43
22. Statler KD, Alexander H, Vagni V, et al. Comparison of seven anesthetic agents on outcome after experimental traumatic brain injury in adult, male rats. J Neurotrauma 2006; 23: 97–108
23. Zohar O, Getslev V, Miller AL, Schreiber S, Pick CG. Morphine protects for head trauma induced cognitive deficits in mice. Neurosci Lett 2006; 394: 239–42
24. Jacobsen KR, Fauerby N, Raida Z, et al. Effects of buprenorphine and meloxicam analgesia on induced cerebral ischemia in C57BL/6 male mice. Lab Anim (NY) 2015; 49: 1037–9
25. Kalliokoski O, Abelson KS, Koch J, et al. The effect of voluntarily ingested buprenorphine on rats subjected to surgically induced global cerebral ischaemia. In Vivo 2010; 24: 641–6
26. Tsenter J, Beni-Adani L, Assaf Y, Alexandrovich AG, Tremboller V, Shohami E. Dynamic changes in the recovery after traumatic brain injury in mice: effect of injury severity on T2-weighted MRI abnormalities, and motor and cognitive functions. J Neurotrauma 2008; 25: 324–33
27. Lein ES, Hawrylycz MJ, Ao N, et al. Genome-wide atlas of gene expression in the adult mouse brain. Nature 2007; 445: 168–76
28. Dong HW. The Allen reference atlas: a digital color brain atlas of the C57Bl/6j male mouse. Hoboken, NJ: John Wiley & Sons Inc.; 2008
29. Pischitutta F, Micotti E, Hay JR, et al. Single severe traumatic brain injury produces progressive pathology with ongoing contralateral white matter damage one year after injury. Exp Neurol 2018; 300: 167–78
30. Schindelin J, Arganda-Carreras I, Frise E, et al. Fiji: an open-source platform for biological-image analysis. Nat Methods 2012; 9: 676–82
31. Sofroniew MV, Vinters HV. Astrocytes: biology and pathology. Acta Neuropathol 2010; 119: 7–35
32. Weiss P. Applications of generating functions in nonparametric tests. Math J 2005; 9: 803–23
33. Keene CS, Bucci DJ. Neurotoxic lesions of retrosplenial cortex disrupt signaled and unsignaled contextual fear conditioning. Behav Neurosci 2008; 122: 1070–7
34. Rudy JW, Huff NC, Matus-Amat P. Understanding contextual fear conditioning: insights from a two-process model. Neurosci Biobehav Rev 2004; 28: 675–85
35. Curzon P, Rustay NR, Browman KE. Cued and contextual fear conditioning for rodents. In: Buccafusco JJ, editor. Methods of behavior analysis in neuroscience. Boca Raton, FL: CRC Press; 2009
36. Troglic L, Wilson YM, Newman AG, Murphy M. Context fear learning specifically activates distinct populations of neurons in amygdala and hypothalamus. Learn Mem 2011; 18: 678–87
37. Xiong Y, Mahmood A, Chopp M. Animal models of traumatic brain injury. Nat Rev Neurosci 2013; 14: 128–42
38. Pottker B, Stober F, Hummel R, et al. Traumatic brain injury causes long-term behavioral changes related to region-specific increases of cerebral blood flow. Brain Struct Funct 2017; 222: 4005–21
39. Loane DJ, Kumar A, Stoica BA, Cabatbat R, Faden AI. Progressive neurodegeneration after experimental brain trauma: association with chronic microglial activation. J Neuropath Exp Neurol 2014; 73: 14–29
40. Dixon CE, Kochanek PM, Yan HQ, et al. One-year study of spatial memory performance, brain morphology, and cholinergic markers after moderate controlled cortical impact in rats. J Neurotrauma 1999; 16: 109–22
41. Till C, Colella B, Verwegen J, Green RE. Postrecovery cognitive decline in adults with traumatic brain injury. Arch Phys Med Rehabil 2008; 89: S25–34
42. Wang HK, Lin SH, Sung PS, et al. Population based study on patients with traumatic brain injury suggests increased risk of dementia. J Neurol Neurosurg Psychiatry 2012; 83: 1080–5
43. Liddelow SA, Guttenplan KA, Clarke LE, et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature 2017; 541: 481–7
44. Tan H, Yang W, Wu C, et al. Assessment of the role of intracranial hypertension and stress on hippocampal cell apoptosis and hypothalamic–pituitary dysfunction after TBI. Sci Rep 2017; 7: 3805
45. Osterstock G, El Yandouzi T, Romano N, et al. Sustained alterations of hypothalamic tanyocytes during post-traumatic hypopituitarism in male mice. Endocrinology 2014; 155: 1887–98
46. Kasturi BS, Stein DG. Traumatic brain injury causes long-term reduction in serum growth hormone and persistent astrocytosis in the cortico-hypothalamic–pituitary axis of adult male rats. J Neurotrauma 2009; 26: 1315–24
47. Bondanelli M, Ambrosio MR, Zatelli MC, De Marinis L, degli Uberti EC. Hypopituitarism after traumatic brain injury. Eur J Endocrinol 2005; 152: 679–91
48. Kraulik D, Zapletalova J, Fryrak Z, Vaverka M. Dysfunction of hypothalamic–hypophysial axis after traumatic brain injury in adults. J Neurosurg 2010; 113: 581–4
49. Kunzthur I, Leuenberger HG. Gerontological data of C57BL/6J mice: I. Sex differences in survival curves. J Gerontol 1975; 30: 157–62
50. Storer JB. Longevity and gross pathology at death in 22 inbred mouse strains. J Gerontol 1966; 21: 404–9
51. Armstrong SP, Banks F, McKittrick TJW, et al. Identification of two mutations (F758W & F758Y) in the N-methyl-d-aspartate receptor glycine-binding site that selectively prevent competitive inhibition by xenon without affecting glycine binding. Anesthesiology 2012; 117: 38–47
52. de Sousa SLM, Dickinson R, Lieb WR, Franks NP. Contrasting synaptic actions of the inhalational general anaesthetics isoflurane and xenon. Anesthesiology 2000; 92: 1055–66
53. Dickinson R, Peterson BK, Banks P, et al. Competitive inhibition at the glycine site of the N-methyl-d-aspartate receptor by the anaesthetics xenon and isoflurane: evidence from molecular modeling and electrophysiology. Anesthesiology 2007; 107: 756–67
54. Franks NP, Dickinson R, de Sousa SLM, Hall AC, Lieb WR. How does xenon produce anaesthesia? Nature 1998; 396: 324
55. Gruss M, Bushell TJ, Bright DF, Lieb WR, Mathie A, Franks NP. Two-pore-domain K⁺ channels are a novel target for the anesthetic gases xenon, nitrous oxide, and cyclopropane. Mol Pharmacol 2004; 65: 443–52
56. Dickinson R, Franks NP. Bench-to-bedside review: molecular pharmacology and clinical use of inert gases in anesthesia and neuroprotection. Crit Care 2010; 14: 229
57. Baker AJ, Moulton RJ, Macmillan VH, Shedden PM. Excitatory amino acids in cerebrospinal fluid following traumatic brain injury in humans. J Neurosurg 1993; 79: 369–72
58. Azzopardi D, Robertson NJ, Bainbridge A, et al. Moderate hypothermia within 6 h of birth plus inhaled xenon versus moderate hypothermia alone after birth asphyxia (TOBY-Xe): a proof-of-concept, open-label, randomised controlled trial. Lancet Neurol 2016; 15: 145–53
59. Dingley J, Tooley J, Liu X, et al. Xenon ventilation during therapeutic hypothermia in neonatal encephalopathy: a feasibility study. Pediatrics 2014; 133: 809–18

Handling editor: H.C. Hemmings Jr